NZ732701A - Compounds, compositions, and methods for increasing cftr activity - Google Patents
Compounds, compositions, and methods for increasing cftr activityInfo
- Publication number
- NZ732701A NZ732701A NZ732701A NZ73270115A NZ732701A NZ 732701 A NZ732701 A NZ 732701A NZ 732701 A NZ732701 A NZ 732701A NZ 73270115 A NZ73270115 A NZ 73270115A NZ 732701 A NZ732701 A NZ 732701A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- cftr
- group
- compound
- hydroxyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 16
- 230000000694 effects Effects 0.000 title claims abstract 14
- 238000000034 method Methods 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title claims 3
- 101150029409 CFTR gene Proteins 0.000 title 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims abstract 31
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims abstract 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- -1 C1-4 alkyoxy Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 201000010064 diabetes insipidus Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims 3
- 229960004508 ivacaftor Drugs 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- GHTGYZMBQPXTCQ-UHFFFAOYSA-N CC1(C)Cc2c(sc(NC(=O)c3ccn[nH]3)c2C(N)=O)C(C)(C)O1 Chemical compound CC1(C)Cc2c(sc(NC(=O)c3ccn[nH]3)c2C(N)=O)C(C)(C)O1 GHTGYZMBQPXTCQ-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- QVDYQHXNAQHIKH-TZIWHRDSSA-N galicaftor Chemical compound FC1(OC2=C(O1)C=CC(=C2)C1(CC1)C(=O)N[C@@H]1C[C@@H](OC2=CC(=CC=C12)OC(F)F)C1=CC=C(C(=O)O)C=C1)F QVDYQHXNAQHIKH-TZIWHRDSSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 claims 1
- JURPNJLVVWTGJR-MLCCFXAWSA-N CC[C@@H](CO)C1=C(NC(C2(CC2)C2=CC=CC(O3)=C2OC3(F)F)=O)N(CC(CO)O)C2=CC=CC(F)=C12 Chemical compound CC[C@@H](CO)C1=C(NC(C2(CC2)C2=CC=CC(O3)=C2OC3(F)F)=O)N(CC(CO)O)C2=CC=CC(F)=C12 JURPNJLVVWTGJR-MLCCFXAWSA-N 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013883 Dwarfism Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- OXHOHEZRNMTKCW-UHFFFAOYSA-N OC(C1=CC(C2=NC(CNC(C3(CC3)C3=CC=CC(O4)=C3OC4(F)F)=O)=CC=C2)=CC=C1)=O Chemical compound OC(C1=CC(C2=NC(CNC(C3(CC3)C3=CC=CC(O4)=C3OC4(F)F)=O)=CC=C2)=CC=C1)=O OXHOHEZRNMTKCW-UHFFFAOYSA-N 0.000 claims 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000025237 Polyendocrinopathy Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229940045109 genistein Drugs 0.000 claims 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 1
- 235000006539 genistein Nutrition 0.000 claims 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000037427 ion transport Effects 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 230000002988 nephrogenic effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000020978 protein processing Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 102220002718 rs121908745 Human genes 0.000 claims 1
- 102200132008 rs75541969 Human genes 0.000 claims 1
- 102200128617 rs75961395 Human genes 0.000 claims 1
- 102220338971 rs762679408 Human genes 0.000 claims 1
- 102200128169 rs77932196 Human genes 0.000 claims 1
- 102200132108 rs80034486 Human genes 0.000 claims 1
- 102200128229 rs80055610 Human genes 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000001177 vas deferen Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096374P | 2014-12-23 | 2014-12-23 | |
| US201562102244P | 2015-01-12 | 2015-01-12 | |
| US201562196839P | 2015-07-24 | 2015-07-24 | |
| US201562199661P | 2015-07-31 | 2015-07-31 | |
| PCT/US2015/000212 WO2016105485A2 (en) | 2014-12-23 | 2015-12-23 | Compounds, compositions, and methods for increasing cftr activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ732701A true NZ732701A (en) | 2022-12-23 |
Family
ID=55168337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ732701A NZ732701A (en) | 2014-12-23 | 2015-12-23 | Compounds, compositions, and methods for increasing cftr activity |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10392372B2 (OSRAM) |
| EP (1) | EP3237411B1 (OSRAM) |
| JP (1) | JP6700284B2 (OSRAM) |
| KR (1) | KR102677444B1 (OSRAM) |
| CN (1) | CN107207487B (OSRAM) |
| AU (3) | AU2015371294B2 (OSRAM) |
| BR (1) | BR112017013710B1 (OSRAM) |
| ES (1) | ES2962673T3 (OSRAM) |
| IL (2) | IL252987B (OSRAM) |
| MA (1) | MA41253A (OSRAM) |
| MX (1) | MX388421B (OSRAM) |
| NZ (1) | NZ732701A (OSRAM) |
| RU (1) | RU2767460C2 (OSRAM) |
| SA (1) | SA517381828B1 (OSRAM) |
| SG (1) | SG11201704859UA (OSRAM) |
| WO (1) | WO2016105485A2 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55940B1 (sr) | 2005-12-28 | 2017-09-29 | Vertex Pharma | Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| KR20190061096A (ko) | 2010-04-22 | 2019-06-04 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
| EP3116870A1 (en) | 2014-03-13 | 2017-01-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2015138909A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| WO2015196071A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| WO2016054560A1 (en) | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| RS60906B1 (sr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| WO2016105477A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| WO2016105484A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| CA2993450C (en) * | 2015-07-24 | 2023-10-24 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| KR20180093882A (ko) | 2015-10-06 | 2018-08-22 | 프로테오스타시스 테라퓨틱스, 인크. | Cftr 조절용 화합물, 조성물, 및 방법 |
| AU2016379388A1 (en) * | 2015-12-22 | 2018-07-12 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
| PL3436446T3 (pl) | 2016-03-31 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
| MX386698B (es) | 2016-04-07 | 2025-03-19 | Proteostasis Therapeutics Inc | Atomos de silicona que contienen analogos de ivacaftor |
| EP3472156B1 (en) | 2016-06-21 | 2023-06-07 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| HUE056716T2 (hu) | 2016-09-30 | 2022-03-28 | Vertex Pharma | Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására |
| KR101912153B1 (ko) * | 2016-11-24 | 2018-10-26 | 이진호 | 극지항해용 자기 부상선 |
| EP3812379A1 (en) | 2016-12-09 | 2021-04-28 | Vertex Pharmaceuticals Incorporated | Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20210069174A1 (en) * | 2017-07-01 | 2021-03-11 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of cystic fibrosis |
| CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
| AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| JP7245834B2 (ja) | 2017-12-08 | 2023-03-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| CN108440455B (zh) * | 2018-04-11 | 2019-06-14 | 上海馨远医药科技有限公司 | 一种3-氧杂环丁烷羧酸的制备方法 |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| JP7386815B2 (ja) * | 2018-05-31 | 2023-11-27 | セルタクシー、エルエルシー | 呼吸器疾患患者の肺増悪を軽減する方法 |
| GB201810071D0 (en) | 2018-06-19 | 2018-08-08 | Univ Oslo Hf | Compounds |
| CN112585130A (zh) | 2018-06-27 | 2021-03-30 | 蛋白质平衡治疗股份有限公司 | 蛋白酶体活性增强化合物 |
| AU2021217225A1 (en) * | 2020-02-07 | 2022-10-06 | University Of South Florida | Inhibition of beta-arrestin oligomerization in tauopathy |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| BR112023016539A2 (pt) * | 2021-02-19 | 2023-11-14 | Kalvista Pharmaceuticals Ltd | Inibidores do fator xiia |
| IL314691A (en) | 2022-02-03 | 2024-10-01 | Vertex Pharma | PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL |
| IL314449A (en) | 2022-02-03 | 2024-09-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
| CA3251045A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS |
| US20250332151A1 (en) | 2022-05-16 | 2025-10-30 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TW202425990A (zh) * | 2022-11-02 | 2024-07-01 | 南韓商日東製藥股份有限公司 | 包含ｃｆｔｒ調節劑化合物之點眼用組成物 |
| CN120136817A (zh) * | 2025-05-16 | 2025-06-13 | 安徽泽升科技股份有限公司 | 一种氧杂环丁烷-3-甲醇和氧杂环丁烷-3-甲醛的制备方法 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3812225A1 (de) | 1988-04-13 | 1989-10-26 | Basf Ag | Isoxazol(isothiazol)-5-carbonsaeureamide |
| AU6788996A (en) | 1995-08-02 | 1997-02-26 | J. Uriach & Cia S.A. | New carboxamides with antifungal activity |
| EP0761654B1 (en) * | 1995-08-24 | 2003-06-18 | Basf Aktiengesellschaft | Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides |
| DK0957099T3 (da) * | 1998-04-15 | 2003-03-17 | Pfizer Prod Inc | Heterocykliske carboxamider |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| JP4901102B2 (ja) * | 2002-05-03 | 2012-03-21 | エクセリクシス， インク． | プロテインキナーゼモジュレーターおよびその使用方法 |
| EP1394159A1 (fr) * | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| NZ546365A (en) | 2003-10-08 | 2010-01-29 | Vertex Pharma | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
| ZA200604578B (en) | 2003-11-14 | 2008-05-28 | Vertex Pharma | Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| CA2565965A1 (en) | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Pde4b inhibitors and uses therefor |
| SE0401969D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidine derivatives |
| US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| JP2006176443A (ja) * | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
| US7812040B2 (en) | 2005-06-22 | 2010-10-12 | Pfizer Inc. | Histamine-3 receptor antagonists |
| JP4822406B2 (ja) | 2005-09-26 | 2011-11-24 | ルネサスエレクトロニクス株式会社 | 表示制御駆動装置および表示システム |
| WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| KR101394245B1 (ko) | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤 |
| TW200815351A (en) | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| BRPI0718162A2 (pt) | 2006-10-20 | 2013-11-26 | Irm Llc | Composição e métodos para modulara os receptores c-kit e pdgfr |
| WO2008070739A1 (en) | 2006-12-06 | 2008-06-12 | Cytokinetics, Inc. | Ksp activators |
| ES2379746T3 (es) | 2007-06-29 | 2012-05-03 | Sk Biopharmaceuticals Co., Ltd. | Composición farmacéutica para la prevención y el tratamiento de la restenosis que comprende los derivados del isoxazol |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| US8211927B2 (en) | 2007-08-02 | 2012-07-03 | MSD, Oss B.V. | 5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009131951A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US20090318429A1 (en) | 2008-04-28 | 2009-12-24 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives |
| AU2010211114A1 (en) | 2009-02-04 | 2011-06-30 | Msd Oss B.V. | Isoxazole-5-carboxamide derivatives |
| CN102421784B (zh) | 2009-03-11 | 2015-09-30 | 杏林制药株式会社 | 作为gsk-3抑制剂的7-环烷基氨基喹诺酮 |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| IN2012DN00352A (OSRAM) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| US8569899B2 (en) | 2009-12-30 | 2013-10-29 | Stmicroelectronics, Inc. | Device and method for alignment of vertically stacked wafers and die |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2012007500A2 (de) | 2010-07-15 | 2012-01-19 | Bayer Cropscience Ag | Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| WO2012121361A1 (ja) | 2011-03-10 | 2012-09-13 | 第一三共株式会社 | ジスピロピロリジン誘導体 |
| CA2736441A1 (en) * | 2011-04-06 | 2012-10-06 | The Regents Of The University Of California | Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors |
| BR112014001933A2 (pt) | 2011-07-29 | 2017-02-21 | Karyopharm Therapeutics Inc | moduladores de transporte nuclear e usos dos mesmos |
| EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
| ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
| US8623860B2 (en) | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
| PL2814812T3 (pl) | 2012-02-16 | 2017-10-31 | Dow Agrosciences Llc | Sposób wytwarzania związków sulfiliminowych |
| UA110436C2 (en) | 2012-03-06 | 2015-12-25 | Zoetis Llc | Antibacterial phenol compounds |
| WO2013146970A1 (ja) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
| WO2014045283A1 (en) | 2012-09-24 | 2014-03-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Restoration of the cftr function by splicing modulation |
| CA2891965A1 (en) | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic cftr correctors |
| WO2014081820A1 (en) | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Small molecule cftr correctors |
| HK1220610A1 (zh) | 2013-03-13 | 2017-05-12 | 弗拉特利发现实验室有限责任公司 | 哒嗪酮化合物和用於治疗囊肿状纤维化的方法 |
| US20140371238A1 (en) | 2013-03-13 | 2014-12-18 | Flatley Discovery Lab | Compounds and methods for the treatment of cystic fibrosis |
| US20160030406A1 (en) | 2013-03-15 | 2016-02-04 | Vertex Pharmaceuticals Incorporated | Correctors acting through msd1 of cftr protein |
| JP6514680B2 (ja) | 2013-03-15 | 2019-05-15 | ディスカバリーバイオメッド， インコーポレイテッド | クマリン誘導体、ならびに嚢胞性線維症、慢性閉塞性肺疾患、及びミスフォールドタンパク質障害の治療における使用方法 |
| LU92578B1 (fr) | 2013-05-07 | 2014-12-15 | Galapagos Nv | Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CA2915975A1 (en) | 2013-06-26 | 2014-12-31 | Proteostasis Therapeutics, Inc. | Methods of modulating cftr activity |
| WO2015051230A1 (en) | 2013-10-04 | 2015-04-09 | Drexel University | Novel compositions useful for inhibiting hiv-1 infection and methods using same |
| WO2015138909A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| EP3116870A1 (en) | 2014-03-13 | 2017-01-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2015196071A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| WO2016054560A1 (en) | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| WO2016105477A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| WO2016105484A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA2993450C (en) | 2015-07-24 | 2023-10-24 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| US20190022071A1 (en) | 2015-08-31 | 2019-01-24 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
| KR20180093882A (ko) | 2015-10-06 | 2018-08-22 | 프로테오스타시스 테라퓨틱스, 인크. | Cftr 조절용 화합물, 조성물, 및 방법 |
| AU2016379388A1 (en) | 2015-12-22 | 2018-07-12 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
| EP3472156B1 (en) | 2016-06-21 | 2023-06-07 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
-
2015
- 2015-12-22 MA MA041253A patent/MA41253A/fr unknown
- 2015-12-23 CN CN201580074407.1A patent/CN107207487B/zh active Active
- 2015-12-23 US US15/539,392 patent/US10392372B2/en active Active
- 2015-12-23 JP JP2017533772A patent/JP6700284B2/ja active Active
- 2015-12-23 BR BR112017013710-0A patent/BR112017013710B1/pt active IP Right Grant
- 2015-12-23 AU AU2015371294A patent/AU2015371294B2/en active Active
- 2015-12-23 MX MX2017008380A patent/MX388421B/es unknown
- 2015-12-23 KR KR1020177020139A patent/KR102677444B1/ko active Active
- 2015-12-23 SG SG11201704859UA patent/SG11201704859UA/en unknown
- 2015-12-23 WO PCT/US2015/000212 patent/WO2016105485A2/en not_active Ceased
- 2015-12-23 ES ES15825647T patent/ES2962673T3/es active Active
- 2015-12-23 RU RU2017126232A patent/RU2767460C2/ru active
- 2015-12-23 EP EP15825647.9A patent/EP3237411B1/en active Active
- 2015-12-23 NZ NZ732701A patent/NZ732701A/en unknown
-
2017
- 2017-06-18 IL IL252987A patent/IL252987B/en active IP Right Grant
- 2017-06-26 SA SA517381828A patent/SA517381828B1/ar unknown
-
2019
- 2019-07-12 US US16/510,406 patent/US11098035B2/en active Active
-
2020
- 2020-08-02 IL IL276426A patent/IL276426A/en unknown
- 2020-10-12 AU AU2020256305A patent/AU2020256305A1/en not_active Abandoned
-
2022
- 2022-09-06 AU AU2022228100A patent/AU2022228100A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ732701A (en) | Compounds, compositions, and methods for increasing cftr activity | |
| IL273752B1 (en) | Ingredients, compounds and methods for increasing cftr activity | |
| HRP20210165T1 (hr) | Čvrsta disperzija amorfnog oblika (r)-1(2,2-difluorobenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamida | |
| NZ746793A (en) | Silicone atoms containing ivacaftor analogues | |
| RU2018116569A (ru) | Соединения, композиции и способы для модуляции cftr | |
| NZ616097A (en) | Pyridyl derivatives as cftr modulators | |
| US20250361211A1 (en) | Deuterated cftr potentiators | |
| NZ603044A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| JP2012521361A5 (OSRAM) | ||
| JP2019513741A5 (OSRAM) | ||
| US20220041557A1 (en) | Deuterated cftr potentiators | |
| JP2011516420A5 (OSRAM) | ||
| JP2013508414A5 (OSRAM) | ||
| EP3235812B1 (en) | Deuterated derivatives of ivacaftor | |
| NZ587545A (en) | Heteroaryl derivatives as cftr modulators | |
| NZ581259A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| NZ598941A (en) | Isoquinoline modulators of ATP-Binding Cassette transporters | |
| HRP20160682T1 (hr) | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline | |
| JP2010539185A5 (OSRAM) | ||
| JP2011506474A5 (OSRAM) | ||
| JP2012514038A5 (OSRAM) | ||
| JP2013501787A5 (OSRAM) | ||
| JP2009521468A5 (OSRAM) | ||
| JP2011513321A5 (OSRAM) | ||
| JP2011505338A5 (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2024 BY COMPUTER PACKAGES INC Effective date: 20231217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2025 BY COMPUTER PACKAGES INC Effective date: 20241130 |